Curcuminoids Target Decreasing Serum Adipocyte-fatty Acid Binding Protein Levels in Their Glucose-lowering Effect in Patients with Type 2 Diabetes.
- Author:
Li Xin NA
1
;
Bo Lin YAN
2
;
Shuo JIANG
1
;
Hong Li CUI
1
;
Ying LI
1
;
Chang Hao SUN
1
Author Information
- Publication Type:Letter
- MeSH: Biomarkers; blood; Blood Glucose; analysis; Curcumin; administration & dosage; pharmacology; therapeutic use; Diabetes Mellitus, Type 2; blood; complications; drug therapy; immunology; Fatty Acid-Binding Proteins; blood; Humans; Hypoglycemic Agents; administration & dosage; pharmacology; therapeutic use; Obesity; blood; complications; drug therapy; immunology; Oxidative Stress; drug effects; immunology; Treatment Outcome
- From: Biomedical and Environmental Sciences 2014;27(11):902-906
- CountryChina
- Language:English
- Abstract: Whether supplementation of curcuminoids decreases serum adipocyte-fatty acid binding protein (A-FABP) level and whether this decrease benefits glucose control is unclear. One-hundred participants (n=50 administered curcuminoids, n=50 administered placebo) from our previous report on the effect of curcuminoids on type 2 diabetes in a 3-month intervention were assessed for levels of serum A-FABP, oxidative stress, and inflammatory biomarkers. Curcuminoids supplementation led to significant decreases in serum A-FABP, C-reactive protein (CRP), tumor necrosis factor-α, and interleukin-6 levels. Curcuminoids supplementation also significantly increased serum superoxide dismutase (SOD) activity. The change in serum A-FABP levels showed positive correlations with changes in levels of glucose, free fatty acids (FFAs), and CRP in subjects supplemented with curcuminoids. Further stepwise regression analysis showed that A-FABP was an independent predictor for levels of FFAs, SOD, and CRP. These results suggest that curcuminoids may exert anti-diabetic effects, at least in part, by reductions in serum A-FABP level. A-FABP reduction is associated with improved metabolic parameters in human type 2 diabetes.
